Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TREPROSTINIL Cause Device physical property issue? 218 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 218 reports of Device physical property issue have been filed in association with TREPROSTINIL (TYVASO). This represents 0.2% of all adverse event reports for TREPROSTINIL.

218
Reports of Device physical property issue with TREPROSTINIL
0.2%
of all TREPROSTINIL reports
8
Deaths
92
Hospitalizations

How Dangerous Is Device physical property issue From TREPROSTINIL?

Of the 218 reports, 8 (3.7%) resulted in death, 92 (42.2%) required hospitalization, and 2 (0.9%) were considered life-threatening.

Is Device physical property issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TREPROSTINIL. However, 218 reports have been filed with the FAERS database.

What Other Side Effects Does TREPROSTINIL Cause?

Dyspnoea (16,348) Headache (14,051) Diarrhoea (11,335) Nausea (10,320) Cough (8,945) Fatigue (7,440) Dizziness (7,405) Infusion site pain (5,169) Vomiting (5,097) Death (4,764)

What Other Drugs Cause Device physical property issue?

SOMATROPIN (2,449) PEGFILGRASTIM (1,376) LEVONORGESTREL (506) CARBIDOPA\LEVODOPA (219) CHLORHEXIDINE\ISOPROPYL ALCOHOL (107) ADALIMUMAB (95) ESTRADIOL (89) BACLOFEN (77) ALBUTEROL (55) ETANERCEPT (55)

Which TREPROSTINIL Alternatives Have Lower Device physical property issue Risk?

TREPROSTINIL vs TREPROSTINIL DIOLAMINE TREPROSTINIL vs TRETINOIN TREPROSTINIL vs TRIAMCINOLONE TREPROSTINIL vs TRIAMCINOLONE ACETONIDE TREPROSTINIL vs TRIAMCINOLONE HEXACETONIDE

Related Pages

TREPROSTINIL Full Profile All Device physical property issue Reports All Drugs Causing Device physical property issue TREPROSTINIL Demographics